Paul Goss

Summary

Affiliation: Princess Margaret Hospital
Country: Canada

Publications

  1. ncbi Current perspectives on radiation-induced breast cancer
    P E Goss
    the Toronto Hospital General Division, Canada
    J Clin Oncol 16:338-47. 1998
  2. ncbi Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial
    Paul E Goss
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
    Semin Oncol 33:S8-12. 2006
  3. ncbi The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats
    Paul E Goss
    Breast Cancer Prevention Program, Princess Margaret Hospital, University Health Network, University of Toronto, Ontario, Canada M5G 2M9
    J Steroid Biochem Mol Biol 92:79-87. 2004
  4. ncbi Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats
    Paul E Goss
    Breast Cancer Prevention Program, Princess Margaret Hospital, University Health Network, University of Toronto, Ontario, Canada
    Clin Cancer Res 10:5717-23. 2004
  5. ncbi The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats
    P E Goss
    Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada M5G 2M9
    Bone 34:384-92. 2004
  6. ncbi Prevention strategies with aromatase inhibitors
    Paul E Goss
    Breast Cancer Prevention Program, Princess Margaret Hospital, Medical Oncology, Toronto, Ontario, Canada
    Clin Cancer Res 10:372S-9S. 2004
  7. ncbi Aromatase inhibitors for chemoprevention
    Paul E Goss
    Medical Oncology, Princess Margaret Hospital, University Health Network, 610 University Avenue, 5 303, Toronto, Ontario, Canada M5G 2M9
    Best Pract Res Clin Endocrinol Metab 18:113-30. 2004
  8. ncbi Breast cancer prevention--clinical trials strategies involving aromatase inhibitors
    Paul E Goss
    Breast Cancer Prevention Program, University of Toronto, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ont, Canada M5G 2M9
    J Steroid Biochem Mol Biol 86:487-93. 2003
  9. ncbi A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
  10. ncbi Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer
    P E Goss
    The Toronto Hospital, Ontario, Canada
    Breast Cancer Res Treat 59:55-68. 2000

Detail Information

Publications65

  1. ncbi Current perspectives on radiation-induced breast cancer
    P E Goss
    the Toronto Hospital General Division, Canada
    J Clin Oncol 16:338-47. 1998
    ..An approach to screening and detection of radiation-induced breast cancer is offered. Primary and secondary prevention strategies are suggested and the need for prospective clinical trials is emphasized...
  2. ncbi Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial
    Paul E Goss
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
    Semin Oncol 33:S8-12. 2006
    ..The re-randomization of MA.17 patients to an additional 5 years of letrozole or to no treatment will provide further insights into the benefits and side effects of long-term treatment...
  3. ncbi The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats
    Paul E Goss
    Breast Cancer Prevention Program, Princess Margaret Hospital, University Health Network, University of Toronto, Ontario, Canada M5G 2M9
    J Steroid Biochem Mol Biol 92:79-87. 2004
    ..Potentially, E(2) + SCH 57068 could be combined for the treatment and prevention of breast cancer or as a novel hormone replacement therapy...
  4. ncbi Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats
    Paul E Goss
    Breast Cancer Prevention Program, Princess Margaret Hospital, University Health Network, University of Toronto, Ontario, Canada
    Clin Cancer Res 10:5717-23. 2004
    ..We studied the effects of EXE, its principal metabolite, 17-hydroexemestane (17-H-EXE), and LET on bone and lipid metabolism in ovariectomized (OVX) rats...
  5. ncbi The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats
    P E Goss
    Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada M5G 2M9
    Bone 34:384-92. 2004
    ..0001) and reduced LDL by 64% compared with OVX controls (P<0.0001). The positive results of EXE on bone and lipid metabolism in the OVX rat model merit further investigation of the effects of EXE in postmenopausal women...
  6. ncbi Prevention strategies with aromatase inhibitors
    Paul E Goss
    Breast Cancer Prevention Program, Princess Margaret Hospital, Medical Oncology, Toronto, Ontario, Canada
    Clin Cancer Res 10:372S-9S. 2004
    ..The efficacy and long-term toxicity data from the aromatase inhibitor prevention trials, and the identification of risk profiles from trial results, are awaited with interest...
  7. ncbi Aromatase inhibitors for chemoprevention
    Paul E Goss
    Medical Oncology, Princess Margaret Hospital, University Health Network, 610 University Avenue, 5 303, Toronto, Ontario, Canada M5G 2M9
    Best Pract Res Clin Endocrinol Metab 18:113-30. 2004
    ..3 study of exemestane with or without celecoxib against placebo. The efficacy and toxicity results of these studies, and the identification of risk profiles from them, are awaited with interest...
  8. ncbi Breast cancer prevention--clinical trials strategies involving aromatase inhibitors
    Paul E Goss
    Breast Cancer Prevention Program, University of Toronto, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ont, Canada M5G 2M9
    J Steroid Biochem Mol Biol 86:487-93. 2003
    ..The aromatase inhibitors offer us the first ever tool to render women virtually free of estrogen and are potentially an exciting tool for the prevention of breast cancer...
  9. ncbi A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
    ..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy...
  10. ncbi Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer
    P E Goss
    The Toronto Hospital, Ontario, Canada
    Breast Cancer Res Treat 59:55-68. 2000
    ..Further studies are needed to confirm its relative efficacy in both receptor positive and negative postmenopausal breast cancer...
  11. ncbi Aromatase inhibitors in the treatment and prevention of breast cancer
    P E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 19:881-94. 2001
    ..The purpose of this article is to provide an overview of the current clinical status and possible future applications of aromatase inhibitors in breast cancer...
  12. ncbi Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer
    P E Goss
    Princess Margaret Hospital, Toronto, Canada
    Breast Cancer Res Treat 64:177-88. 2000
    ..The clinical responses observed, together with our preclinical results, confirm liarozole's dual mechanism of action and provide a rationale for further evaluation of RAMBAs in the treatment of breast cancer...
  13. ncbi Chemoprevention with aromatase inhibitors--trial strategies
    P E Goss
    Princess Margaret Hospital, University Health Network, 610 University Avenue, Room 5 303, Ontario, M5G 2M9, Toronto, Canada
    J Steroid Biochem Mol Biol 79:143-9. 2001
    ..Issues such as dose, schedule, therapeutic index and mono versus combination therapy are important to define...
  14. ncbi Preliminary data from ongoing adjuvant aromatase inhibitor trials
    P E Goss
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 7:4397s-4401s; discussion 4411s-4412s. 2001
    ..Aromatase inhibitors are poised to alter the treatment paradigm of breast cancer and hopefully improve outcome for a substantial number of patients...
  15. ncbi Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors
    Paul E Goss
    Breast Cancer Prevention Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Drugs 62:957-66. 2002
    ..Pilot studies of chemoprevention are also being undertaken. The aromatase inhibitors are an important new addition to the armamentarium of breast cancer therapy...
  16. ncbi Anti-aromatase agents in the treatment and prevention of breast cancer
    Paul Goss
    Breast Cancer Prevention Program at the Princess Margaret Hospital, Toronto, Ontario, Canada
    Cancer Control 9:2-8. 2002
    ..These studies will provide long-term data in healthy women and will help to differentiate anti-aromatase agents, in terms of their efficacy in the treatment of breast cancer and their effects on end organs...
  17. ncbi Letrozole for the management of breast cancer
    Paul E Goss
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, 5 303, Toronto, Ontario, M5G 2M9, Canada
    Expert Rev Anticancer Ther 2:249-60. 2002
    ..Nevertheless, the superior clinical efficacy and survival data of letrozole suggest that it has the potential to displace tamoxifen as the gold standard in breast cancer treatment in the coming years...
  18. ncbi Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer
    Paul Goss
    Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:4961-6. 2007
    ..To compare time to progression (TTP) with a steroidal aromatase inhibitor (AI) atamestane (ATA) combined with toremifene (TOR; complete estrogen blockade) versus letrozole (LET) in receptor-positive advanced breast cancer (ABC)...
  19. doi Exemestane for breast-cancer prevention in postmenopausal women
    Paul E Goss
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 364:2381-91. 2011
    ..Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer...
  20. ncbi Application of aromatase inhibitors in endocrine responsive breast cancers
    Paul Goss
    Massachusetts General Hospital, 55 Fruit Street, LRH 302, Boston, MA 02114, USA
    Breast 16:S114-9. 2007
    ....
  21. doi New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target?
    Paul Goss
    Massachusetts General Hospital Cancer Center, and Department of Medicine, Harvard Medical School, Boston, MA, USA
    APMIS 116:552-68. 2008
    ..A better understanding of mechanisms responsible for tumor dormancy and recurrence will be important for improving care of patients at risk for late-developing metastases...
  22. doi Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial
    Hadine Joffe
    Perinatal and Reproductive Psychiatry Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Menopause 17:908-16. 2010
    ..Alternative strategies are needed. We hypothesized that augmentation of SSRI/SNRI therapy with hypnotic agents would optimize hot flash therapy by improving sleep and quality of life...
  23. ncbi Summary of aromatase inhibitor trials: the past and future
    Paul Goss
    Massachusetts General Hospital Cancer Center, Harvard Medical School, LRH 302, 55 Fruit Street, Boston, MA 02114, USA
    J Steroid Biochem Mol Biol 106:40-8. 2007
    ..Both tumor and host signatures are being pursued to this end. Optimizing, expanding and extending endocrine therapy is likely to add further to patient outcome...
  24. ncbi Lapatinib-associated toxicity and practical management recommendations
    Beverly Moy
    Massachusetts General Hospital Cancer Center, Gillette Center for Women s Cancers, Lawrence House, LRH 304, Boston, MA 02114, USA
    Oncologist 12:756-65. 2007
    ..Cardiac toxicity is rarely seen with lapatinib. This paper reviews lapatinib-associated toxicities and provides practical management recommendations based on available data...
  25. ncbi Breast cancer adjuvant endocrine therapy
    Tessa Cigler
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Cancer J 13:148-55. 2007
    ..The hope is that continued advances in endocrine therapy will translate into improved survival among both pre- and postmenopausal women with receptor-positive breast cancer...
  26. ncbi Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy
    Richard J Santen
    University of Virginia, Charlottesville, VA 22908, United States
    Steroids 72:666-71. 2007
    ..Several pharmacological and clinical considerations suggest that GC/MS/MS should become the preferred method for monitoring aromatase inhibitor therapy...
  27. ncbi TEACH: Tykerb evaluation after chemotherapy
    Beverly Moy
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Clin Breast Cancer 7:489-92. 2007
  28. ncbi Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example
    Joseph Pater
    Cancer Research Institute, Queen s University, 10 Stuart St, Kingston, ON, Canada K7L 3N6
    Breast Cancer Res Treat 108:265-9. 2008
    ..We conclude that although the decision to release the results of the interim analysis of MA17 and allow patients on placebo to take letrozole was justified, methods for analyzing and interpreting interim results can be improved...
  29. ncbi Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
    Paul E Goss
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2006-11. 2007
    ..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status...
  30. pmc Letrozole in the extended adjuvant setting: MA.17
    Paul E Goss
    Massachusetts General Hospital Cancer Center, 55 Fruit Street, Cox Bldg, Room 640, Boston, MA 02114, USA
    Breast Cancer Res Treat 105:45-53. 2007
    ....
  31. ncbi Update on the use of letrozole in breast cancer
    Melinda Wu
    University of Toronto
    Expert Opin Pharmacother 8:2329-45. 2007
    ..g., node-positive disease, prior chemotherapy). Both the efficacy and safety of letrozole for the adjuvant treatment of breast cancer are reviewed...
  32. doi Addressing the future: combination with targeted therapies, adjuvant setting and beyond
    Paul E Goss
    Massachusetts General Hospital Cancer Center, USA
    Anticancer Drugs 19:S3-5. 2008
    ..In particular, targeted therapies either alone or in combination with AIs may improve clinical outcomes--the results of ongoing clinical trials will shape the future treatment of breast cancer...
  33. doi Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
    Paul E Goss
    Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
    J Clin Oncol 26:1948-55. 2008
    ..When the trial was unblinded, patients who received placebo (PLAC) were offered LET...
  34. doi Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17
    Hyman B Muss
    University of Vermont College of Medicine, 1 South Prospect St, Saint Joseph 3400, Burlington, VT 05401, USA
    J Clin Oncol 26:1956-64. 2008
    ..Breast cancer incidence increases with age and more than 1,300 women age 70 years or older were enrolled onto MA.17, making it ideal to explore the benefits, toxicities, and quality of life (QOL) impact of letrozole on older women...
  35. pmc Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer
    Judith Anne W Chapman
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, 10 Stuart St, Kingston, ON, Canada
    J Natl Cancer Inst 100:252-60. 2008
    ..We examined factors associated with cause-specific death in a large cohort of breast cancer patients treated with extended adjuvant endocrine therapy...
  36. doi National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women
    Paul E Goss
    Harvard Medical School, Boston, MA, USA
    Clin Breast Cancer 7:895-900. 2007
  37. pmc Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
    Paul E Goss
    Massachusetts General Hospital, 55 Fruit Street, LRH 302, Boston, MA 02114, USA
    Breast Cancer Res 9:R52. 2007
    ..This study was designed to compare the effects of exemestane with the nonsteroidal aromatase inhibitors anastrozole and letrozole on serum and urine levels of biomarkers of bone turnover in healthy postmenopausal women...
  38. ncbi Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:700-9. 2008
    ..Outstanding issues to optimize AI therapy include identifying the optimal duration, agent, and patients for these therapies...
  39. ncbi Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference
    Steven E Come
    Breast Cancer Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 112:673-8. 2008
    ..All of this has and continues to contribute to a growing understanding of how to optimize the use of endocrine agents in both treating and preventing breast cancer...
  40. ncbi Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen
    Christopher M Booth
    Cancer 109:1927-8; author reply 1928. 2007
  41. pmc Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model
    Paul E Goss
    Breast Cancer Research, Massachusetts General Hospital Cancer Center, Breast Cancer Disease Program, Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    BMC Cancer 7:26. 2007
    ..Our objective was to determine the effects of liarozole alone or in combination with tamoxifen on the N-methyl-N-nitrosourea (MNU)-induced rat mammary carcinoma model, as well as on the uterus in ovariectomized immature rats...
  42. ncbi The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer
    Paula D Ryan
    Massachusetts General Hospital, Boston, MA 02114, USA
    Nat Clin Pract Oncol 2:596-7. 2005
  43. ncbi Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women
    Timothy J Whelan
    McMaster University, Hamilton, Canada
    J Clin Oncol 23:6931-40. 2005
    ..To evaluate the impact of letrozole compared with placebo after adjuvant tamoxifen on quality of life (QOL) in the MA.17 trial...
  44. ncbi Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
    Paul E Goss
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Natl Cancer Inst 97:1262-71. 2005
    ..This report presents updated findings from the trial...
  45. ncbi Advances in adjuvant hormonal therapy for postmenopausal women
    Kathrin Strasser-Weippl
    First Medical Department with Medical Oncology, Wilhelminen Hospital, Vienna, Austria
    J Clin Oncol 23:1751-9. 2005
  46. ncbi Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer
    Paul E Goss
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
    Semin Oncol 31:15-22. 2004
    ..This is the first demonstration that extended adjuvant therapy after standard tamoxifen in postmenopausal women with early breast cancer has a clinically significant impact on outcome...
  47. ncbi Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:327S-330S. 2004
  48. ncbi Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer
    Nadine Tchen
    Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 21:4175-83. 2003
    ..Here, we determine their incidence and severity, and interrelationships between them and quality of life...
  49. ncbi Prevention of breast cancer using SERMs and aromatase inhibitors
    Kathrin Strassmer-Weippl
    1st Medical Department with Medical Oncology, Wilhelminen Hospital, Vienna, Austria
    J Mammary Gland Biol Neoplasia 8:5-18. 2003
    ..In this paper, the available data on SERMs including tamoxifen and raloxifene in breast cancer prevention and the data pointing to the efficacy of aromatase inhibitors in this setting are outlined...
  50. ncbi Emerging role of aromatase inhibitors in the adjuvant setting
    Paul E Goss
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Am J Clin Oncol 26:S27-33. 2003
    ..These are to determine the end-organ effects of the inhibitors and include measurements of quality of life, bone and lipid metabolism, and endometrial effects. This review addresses the clinical implications of these studies of AIs...
  51. ncbi Bone loss with exemestane: Is the jury still out?
    Angela M Cheung
    J Clin Oncol 23:9433-4; author reply 9433-5. 2005
  52. ncbi Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective
    Jonathan Karnon
    School of Health and Related Research, University of Sheffield, Sheffield, UK
    Pharmacoeconomics 24:237-50. 2006
    ..The objective of this evaluation was to extrapolate the findings from the MA17 trial to estimate the lifetime cost effectiveness of letrozole in this setting...
  53. ncbi Aromatase inhibitors and bone health in women with breast cancer
    Amy Jo Chien
    Department of Internal Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 24:5305-12. 2006
  54. ncbi Lapatinib: current status and future directions in breast cancer
    Beverly Moy
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Oncologist 11:1047-57. 2006
    ..Our improved understanding of the biology of breast cancer and the use of biomarkers for identification of specific subtypes is allowing us to bring patient-specific novel therapies such as lapatinib to the clinic...
  55. ncbi The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model
    Paul E Goss
    Breast Cancer Research, Massachusetts General Hospital Cancer Center, Breast Cancer Disease Program, Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Breast Cancer Res Treat 103:293-302. 2007
    ..ATA is distinct from LET on end-organ function and this favorable profile makes clinical testing of this steroidal aromatase inhibitor of interest in the clinical setting...
  56. ncbi Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches
    Beverly Moy
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 12:4790-3. 2006
    ..This article reviews the problem of resistance to hormonal therapy and addresses potential approaches to overcome intrinsic or acquired mechanisms of resistance...
  57. ncbi Adjuvant hormonal therapy in peri- and postmenopausal breast cancer
    Paula D Ryan
    Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, Massachusetts 02114, USA
    Oncologist 11:718-31. 2006
    ..Areas of active investigation include the mechanisms of resistance to endocrine therapy with tamoxifen and AIs and clinical strategies to overcome this resistance...
  58. ncbi Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17
    Edith A Perez
    St Michael s Hospital, Toronto, Canada
    J Clin Oncol 24:3629-35. 2006
    ..17B evaluated bone turnover markers and bone mineral density (BMD) in postmenopausal women randomly assigned to MA.17, a placebo-controlled trial of letrozole after standard adjuvant tamoxifen...
  59. ncbi Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer
    Lilian U Thompson
    Department of Nutritional Sciences, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 11:3828-35. 2005
    ..This study examined, in a randomized double-blind placebo-controlled clinical trial, the effects of dietary flaxseed on tumor biological markers and urinary lignan excretion in postmenopausal patients with newly diagnosed breast cancer...
  60. ncbi Aromatase inhibitor withdrawal response in metastatic breast cancer
    Tessa Cigler
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 24:1955-6. 2006
  61. ncbi Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006
    ..Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes...
  62. doi The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer
    Paula D Ryan
    Massachusetts General Hospital, LRH 308, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Oncologist 13:16-24. 2008
    ..In this manuscript, the rationale for targeting the insulin-like growth factor system is reviewed in addition to a summary of the available clinical trial data...
  63. pmc Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 117:2104-13. 2008
    ..Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events...
  64. pmc The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells
    Peixiang Wang
    Department of Medicine, University of Toronto, 67 College Street, Toronto, ON, Canada M5G 2M1
    Biochem J 375:199-205. 2003
    ..These observations indicate that OCT3 protein is selectively expressed in human breast cancer cells, and its expression may be implicated in mammary gland tumorigenesis via up-regulating FGF-4 expression...
  65. ncbi Specific homeodomain-DNA interactions are required for HOX11-mediated transformation
    Bronwyn M Owens
    Department of Hematopoiesis, Holland Laboratory, American Red Cross, Rockville, MD 20855, USA
    Blood 101:4966-74. 2003
    ..We conclude that dysregulated expression of a particular set of downstream target genes by DNA binding via the homeodomain is of central importance for leukemia initiation mediated by HOX11...